Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591266 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
A Phase 3 study of Hypertension, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 566
- Enrollment target
- 20
- Study locations
NCT00591266 is a Phase 3 study of Hypertension that has completed, run by Takeda. The registered enrollment target is 566 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00591266, a Phase 3 study of Hypertension, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 566 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.
Conditions Studied
Interventions
- DRUG Amlodipine
- DRUG Azilsartan Medoxomil and amlodipine
Study Locations (20)
California
- - Anaheim
- - Beverly Hills
- - Burbank
- - Burlingame
- - La Jolla
- - Orange
- - Roseville
- - Tustin
Florida
- - Hialeah
- - Longwood
- - Tampa
Arizona
- - Mesa
- - Phoenix
Illinois
- - Chicago
- - Gurnee
Colorado
- - Wheat Ridge
Delaware
- - Newark
District of Columbia
- - Washington D.C.
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 566 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591266
The ClinicalTrials.gov registry entry for NCT00591266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 566 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Amlodipine is the first listed.
NCT00591266 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00591266 about?
NCT00591266 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension". The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.
What is the current status of trial NCT00591266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 566 participants. The study started on 2007-10. Estimated completion is 2009-04.
What conditions does trial NCT00591266 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00591266?
The interventions under investigation include: Amlodipine (DRUG), Azilsartan Medoxomil and amlodipine (DRUG).
Who is sponsoring clinical trial NCT00591266?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00591266 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.